India’s Jubilant Shakes Hands With Endo Pharma For Drug Discovery, Strikes Its Sixth Partnership In 18 Months
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Jubilant Biosys - a subsidiary of Indian pharmaceutical company Jubilant Organosys - is riding high on the collaborative research theme between Indian and multinational drug companies
You may also be interested in...
Building Trust, Technology Competence Can Boost Partnering Prospects For Indian, U.S. Companies
MUMBAI - In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ( 'Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For 'Niche Busters' And Stem Cells,' PharmAsia News, May 23, 2011 ). In the second story, PharmAsia News' India bureau spoke with Biogen Idec SVP Gunther Winkler, who discussed the big biotech's strategy in India and important policy decisions facing the Indian government ( 'Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance,' PharmAsia News, June 13, 20110.
Building Trust, Technology Competence Can Boost Partnering Prospects For Indian, U.S. Companies
MUMBAI - In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ( 'Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For 'Niche Busters' And Stem Cells,' PharmAsia News, May 23, 2011 ). In the second story, PharmAsia News' India bureau spoke with Biogen Idec SVP Gunther Winkler, who discussed the big biotech's strategy in India and important policy decisions facing the Indian government ( 'Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance,' PharmAsia News, June 13, 20110.
AstraZeneca, Jubilant Biosys Join Hands For Leads In Neuroscience
MUMBAI - Collaborative research between Indian and multinational drug companies gained further ground as Jubilant Biosys signed an agreement with AstraZeneca for delivering novel drug candidates to strengthen its preclinical pipeline. Based out of Bangalore, Jubilant Biosys is the research arm of Jubilant Organosys